Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer

Affiliations

Editorial

Jarred P Reed et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S309.

doi: 10.21037/atm.2019.10.27.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer-reply to the editors.
Tinsley N, Graham DM, Cook N. Tinsley N, et al. Ann Transl Med. 2020 Feb;8(4):139. doi: 10.21037/atm.2019.12.06. Ann Transl Med. 2020. PMID: 32175431 Free PMC article. No abstract available.

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, Krebs M, Carter L, Thistlethwaite F, Graham D, Cook N. Tinsley N, et al. Oncologist. 2020 Jan;25(1):55-63. doi: 10.1634/theoncologist.2019-0160. Epub 2019 Jul 10. Oncologist. 2020. PMID: 31292268 Free PMC article.

1. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104-8. 10.1126/science.aao3290 - DOI - PMC - PubMed
1. Geva-Zatorsky N, Sefik E, Kua L, et al. Mining the Human Gut Microbiota for Immunomodulatory Organisms. Cell 2017;168:928-43.e11. 10.1016/j.cell.2017.01.022 - DOI - PMC - PubMed
1. Ahmed J, Kumar A, Parikh K, et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology 2018;7:e1507670. 10.1080/2162402X.2018.1507670 - DOI - PMC - PubMed
1. Derosa L, Routy B, Kroemer G, et al. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. Oncoimmunology 2018;7:e1434468. 10.1080/2162402X.2018.1434468 - DOI - PMC - PubMed
1. Sen S, Carmagnani Pestana R, Hess K, et al. Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. Ann Oncol 2018;29:2396-8. 10.1093/annonc/mdy453 - DOI - PMC - PubMed